The clinical characteristics of the AA patients possessing HLA-A allele–lacking leukocytes
| Cases . | PB count . | % of GPI-AP−granulocytes . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Case no. . | Age/sex . | Original diagnosis . | Disease duration, y . | Treatment . | Response to treatment . | Leukocyte/ANC, ×109/L . | Hemoglobin, g/dL . | Platelet, ×109/L . | Reticulocyte, ×106/L . | At diagnosis . | At sampling . |
| 1 | 84/F | SAA | 8 | ATG + CsA | CR | 4.03/2.22 | 11.1 | 16.8 | 60 | 0.050 | NE |
| 2 | 79/F | NSAA | 12 | CsA | CR | 3.62/2.36 | 12.3 | 133 | 63 | 0.022 | 0.001 |
| 3 | 38/F | NSAA | 14 | CsA | CR | 5.47/4.44 | 11.9 | 136 | 75 | 1.050 | 0.001 |
| 4 | 92/F | SAA | 17 | CsA | CR | 3.43/1.67 | 11.8 | 98 | 38 | 0.005 | NE |
| 5 | 44/M | SAA | 11 | AS | CR | 3.92/2.88 | 13.7 | 182 | 37 | 0 | NE |
| 6 | 66/F | SAA | 16 | ATG + CsA | CR | 5.78/3.29 | 10.9 | 196 | 49 | 0.367 | NE |
| 7 | 39/F | VSAA | 15 | ATG + CsA | CR | 4.57/2.58 | 14.3 | 173 | 68 | 0 | NE |
| 8 | 74/F | NSAA | 25 | CsA | CR | 4.21/2.31 | 13.9 | 167 | NE | 0 | NE |
| 9 | 27/M | NSAA | 14 | ATG + CsA | CR | 2.44/1.30 | 14.8 | 132 | 68 | 1.140 | 0.052 |
| 10 | 42/M | SAA | 10 | CsA | CR | 3.00/1.74 | 14.3 | 159 | 63 | 0.180 | NE |
| 11 | 54/M | NSAA | 2 | CsA + AS | CR | 3.21/1.54 | 12.3 | 109 | 75 | 3.500 | NE |
| 12 | 53/F | VSAA | 3 | Romiplostim | CR | 6.30/3.81 | 14.2 | 147 | 47 | 0 | NE |
| 13 | 50/M | NSAA | 30 | CsA + AS | CR | 4.32/2.57 | 14.4 | 78 | 35 | 0 | NE |
| 14 | 58/M | SAA | 11 | ATG + CsA | CR | 3.76/1.77 | 14.4 | 208 | 59 | 0 | NE |
| 15 | 55/F | PNH | 13 | CsA | CR | 3.54/2.29 | 14 | 111 | 79 | 39.16 | 0.001 |
| →NSAA | |||||||||||
| Cases . | PB count . | % of GPI-AP−granulocytes . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Case no. . | Age/sex . | Original diagnosis . | Disease duration, y . | Treatment . | Response to treatment . | Leukocyte/ANC, ×109/L . | Hemoglobin, g/dL . | Platelet, ×109/L . | Reticulocyte, ×106/L . | At diagnosis . | At sampling . |
| 1 | 84/F | SAA | 8 | ATG + CsA | CR | 4.03/2.22 | 11.1 | 16.8 | 60 | 0.050 | NE |
| 2 | 79/F | NSAA | 12 | CsA | CR | 3.62/2.36 | 12.3 | 133 | 63 | 0.022 | 0.001 |
| 3 | 38/F | NSAA | 14 | CsA | CR | 5.47/4.44 | 11.9 | 136 | 75 | 1.050 | 0.001 |
| 4 | 92/F | SAA | 17 | CsA | CR | 3.43/1.67 | 11.8 | 98 | 38 | 0.005 | NE |
| 5 | 44/M | SAA | 11 | AS | CR | 3.92/2.88 | 13.7 | 182 | 37 | 0 | NE |
| 6 | 66/F | SAA | 16 | ATG + CsA | CR | 5.78/3.29 | 10.9 | 196 | 49 | 0.367 | NE |
| 7 | 39/F | VSAA | 15 | ATG + CsA | CR | 4.57/2.58 | 14.3 | 173 | 68 | 0 | NE |
| 8 | 74/F | NSAA | 25 | CsA | CR | 4.21/2.31 | 13.9 | 167 | NE | 0 | NE |
| 9 | 27/M | NSAA | 14 | ATG + CsA | CR | 2.44/1.30 | 14.8 | 132 | 68 | 1.140 | 0.052 |
| 10 | 42/M | SAA | 10 | CsA | CR | 3.00/1.74 | 14.3 | 159 | 63 | 0.180 | NE |
| 11 | 54/M | NSAA | 2 | CsA + AS | CR | 3.21/1.54 | 12.3 | 109 | 75 | 3.500 | NE |
| 12 | 53/F | VSAA | 3 | Romiplostim | CR | 6.30/3.81 | 14.2 | 147 | 47 | 0 | NE |
| 13 | 50/M | NSAA | 30 | CsA + AS | CR | 4.32/2.57 | 14.4 | 78 | 35 | 0 | NE |
| 14 | 58/M | SAA | 11 | ATG + CsA | CR | 3.76/1.77 | 14.4 | 208 | 59 | 0 | NE |
| 15 | 55/F | PNH | 13 | CsA | CR | 3.54/2.29 | 14 | 111 | 79 | 39.16 | 0.001 |
| →NSAA | |||||||||||
ANC, absolute neutrophil count; AS, anabolic steroids; ATG, antithymocyte globulin; CR, complete response; CsA, cyclosporine; F, female; GPI-AP−, glycosylphosphatidylinositol-anchored membrane proteins deficient; M, male; NE, not evaluated; NSAA, nonsevere aplastic anemia; PB, peripheral blood; PNH, paroxysmal nocturnal hemoglobinuria; SAA, severe aplastic anemia; VSAA, very severe aplastic anemia.